Cue Net Invested Capital from 2010 to 2024
CUE Stock | USD 1.89 0.02 1.07% |
Net Invested Capital | First Reported 2010-12-31 | Previous Quarter 45.2 M | Current Value 65.7 M | Quarterly Volatility 10.9 M |
Check Cue Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cue main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Interest Expense of 1.2 M or Selling General Administrative of 11.7 M, as well as many exotic indicators such as Price To Sales Ratio of 20.9, Dividend Yield of 0.0 or PTB Ratio of 3.09. Cue financial statements analysis is a perfect complement when working with Cue Biopharma Valuation or Volatility modules.
Cue | Net Invested Capital |
Latest Cue Biopharma's Net Invested Capital Growth Pattern
Below is the plot of the Net Invested Capital of Cue Biopharma over the last few years. It is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. Cue Biopharma's Net Invested Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cue Biopharma's overall financial position and show how it may be relating to other accounts over time.
Net Invested Capital | 10 Years Trend |
|
Net Invested Capital |
Timeline |
Cue Net Invested Capital Regression Statistics
Arithmetic Mean | 62,162,121 | |
Geometric Mean | 61,083,229 | |
Coefficient Of Variation | 17.49 | |
Mean Deviation | 7,024,133 | |
Median | 64,107,178 | |
Standard Deviation | 10,873,333 | |
Sample Variance | 118.2T | |
Range | 44.9M | |
R-Value | (0.06) | |
Mean Square Error | 126.8T | |
R-Squared | 0 | |
Significance | 0.82 | |
Slope | (155,219) | |
Total Sum of Squares | 1655.2T |
Cue Net Invested Capital History
About Cue Biopharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Cue Biopharma income statement, its balance sheet, and the statement of cash flows. Cue Biopharma investors use historical funamental indicators, such as Cue Biopharma's Net Invested Capital, to determine how well the company is positioned to perform in the future. Although Cue Biopharma investors may use each financial statement separately, they are all related. The changes in Cue Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cue Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cue Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cue Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Net Invested Capital | 45.2 M | 65.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:Check out the analysis of Cue Biopharma Correlation against competitors. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Cue Stock analysis
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Stocks Directory Find actively traded stocks across global markets | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Cue Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.07) | Revenue Per Share 0.149 | Quarterly Revenue Growth 8.182 | Return On Assets (0.47) | Return On Equity (1.18) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.